1. Home
  2. MLYS vs MNTK Comparison

MLYS vs MNTK Comparison

Compare MLYS & MNTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Mineralys Therapeutics Inc.

MLYS

Mineralys Therapeutics Inc.

HOLD

Current Price

$26.91

Market Cap

1.9B

Sector

Health Care

ML Signal

HOLD

Logo Montauk Renewables Inc.

MNTK

Montauk Renewables Inc.

HOLD

Current Price

$1.14

Market Cap

194.2M

Sector

Utilities

ML Signal

HOLD

Company Overview

Basic Information
Metric
MLYS
MNTK
Founded
2019
1980
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Natural Gas Distribution
Sector
Health Care
Utilities
Exchange
Nasdaq
Nasdaq
Market Cap
1.9B
194.2M
IPO Year
2023
2020

Fundamental Metrics

Financial Performance
Metric
MLYS
MNTK
Price
$26.91
$1.14
Analyst Decision
Strong Buy
Hold
Analyst Count
6
1
Target Price
$48.67
$4.00
AVG Volume (30 Days)
1.2M
331.2K
Earning Date
03-12-2026
03-11-2026
Dividend Yield
N/A
N/A
EPS Growth
37.43
N/A
EPS
N/A
0.01
Revenue
N/A
$176,382,000.00
Revenue This Year
N/A
$21.75
Revenue Next Year
N/A
$17.64
P/E Ratio
N/A
$119.00
Revenue Growth
N/A
0.37
52 Week Low
$10.44
$1.07
52 Week High
$47.65
$2.78

Technical Indicators

Market Signals
Indicator
MLYS
MNTK
Relative Strength Index (RSI) 53.41 35.66
Support Level $26.85 N/A
Resistance Level $30.53 $2.07
Average True Range (ATR) 1.51 0.13
MACD 0.24 -0.00
Stochastic Oscillator 72.39 15.85

Price Performance

Historical Comparison
MLYS
MNTK

About MLYS Mineralys Therapeutics Inc.

Mineralys Therapeutics Inc is a biopharmaceutical company focused on developing medicines to target diseases driven by dysregulated aldosterone. The Company's product candidate, lorundrostat, is a proprietary, orally administered, aldosterone synthase inhibitor that the Company is developing for the treatment of cardiorenal conditions affected by dysregulated aldosterone, including hypertension and related comorbidities, such as chronic kidney disease and obstructive sleep apnea. Its product candidate, lorundrostat, is a proprietary, orally administered, selective ASI that is designed to reduce aldosterone levels by inhibiting CYP11B2, the enzyme responsible for producing the hormone.

About MNTK Montauk Renewables Inc.

Montauk Renewables Inc is a renewable energy company. It specializes in the recovery and processing of biogas from landfills and other non-fossil fuel sources for beneficial use as a replacement for fossil fuels. The firm develops, owns, and operates RNG projects that supply renewable fuel into the transportation and electrical power sectors. Montauk operates in two segments namely Renewable Natural Gas and Renewable Electricity Generation. It generates a majority of its revenue from the Renewable Natural Gas segment.

Share on Social Networks: